Rechon Signs Exclusive License and Distribution Agreement to Manufacture and Commercialize Zolpimist® outside the US and Canada
Rechon Life Science AB announces its entry into an exclusive license and distribution agreement with NovaDel Pharma Inc., where Rechon is to manufacture and commercialize Zolpimist® outside the United States and Canada.
Zolpimist is the oral spray formulation of zolpidem tartrate for the treatment of insomnia, approved by the FDA in December of 2008, developed by NovaDel and manufactured by Rechon.
Insomnia is a sleep disorder whose sufferers experience inadequate or poor quality sleep and report one or more of the following: difficulty initiating sleep, difficulty maintaining sleep, and waking up too early.
Zolpimist oral spray offers the benefit of a faster rise in drug blood levels potentially leading to a faster onset of action, without having to take water.
Roland Holmqvist, CEO of Rechon Life Science AB expressed that, “This license and distribution agreement is offering a great opportunity for a successful introduction of Zolpimist outside the United States and Canada. We look forward to this extended partnership with NovaDel and we are impressed with NovaDel’s efficient oral spray drug delivery technology as used in Zolpimist.”
Steven B. Ratoff, Chairman and CEO of NovaDel Pharma Inc. said, “This agreement expands the market opportunity for Zolpimist to the world outside the U.S. We believe that Rechon, with its relationships with pharmaceutical marketers around the globe, has the ability to build a solid position for Zolpimist in the market for prescription sleep aids.”
To find out more about Rechon Life Science AB please visit our website at www.rechon.com
or be in contact with Roland Holmqvist, CEO of Rechon, firstname.lastname@example.org
, +46 709 48 24 24 if you are intrested in Zolpimist.
About Rechon Life Science AB
Rechon Life Science is a complete pharmaceutical company providing manufacturing services for pharmaceutical and life sciences companies, of non-sterile, sterile and aseptic liquids from small scale batches for clinical trials up to full-scale manufacturing. Our facility operates under cGMP and we are regularly inspected by the Swedish Medical Products Agency, US FDA and other Health Authorities and can supply the commercial markets worldwide including US, Japan and Europe. Rechon assists with analytical, microbiological and stability testing, clinical services, QP release and regulatory filing support.